JP2021522162A - 抗ｒｏｒ抗体構築物 - Google Patents

抗ｒｏｒ抗体構築物 Download PDF

Info

Publication number
JP2021522162A
JP2021522162A JP2020556851A JP2020556851A JP2021522162A JP 2021522162 A JP2021522162 A JP 2021522162A JP 2020556851 A JP2020556851 A JP 2020556851A JP 2020556851 A JP2020556851 A JP 2020556851A JP 2021522162 A JP2021522162 A JP 2021522162A
Authority
JP
Japan
Prior art keywords
domain
antigen
amino acid
ror
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020556851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522162A5 (https=
Inventor
ルーカス ベイリー，
ルーカス ベイリー，
チューフェイ リー，
チューフェイ リー，
マルゴルザータ アグニェシュカ ノキュラ−ルゴウスカ，
マルゴルザータ アグニェシュカ ノキュラ−ルゴウスカ，
ブライアン グレーザー，
ブライアン グレーザー，
Original Assignee
エグゼリクシス， インコーポレイテッド
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド, エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2021522162A publication Critical patent/JP2021522162A/ja
Publication of JP2021522162A5 publication Critical patent/JP2021522162A5/ja
Priority to JP2023172867A priority Critical patent/JP2023168551A/ja
Priority to JP2025117193A priority patent/JP2025137618A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020556851A 2018-04-18 2019-04-18 抗ｒｏｒ抗体構築物 Pending JP2021522162A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023172867A JP2023168551A (ja) 2018-04-18 2023-10-04 抗ｒｏｒ抗体構築物
JP2025117193A JP2025137618A (ja) 2018-04-18 2025-07-11 抗ｒｏｒ抗体構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659635P 2018-04-18 2018-04-18
US62/659,635 2018-04-18
PCT/US2019/028051 WO2019204564A1 (en) 2018-04-18 2019-04-18 Anti-ror antibody constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023172867A Division JP2023168551A (ja) 2018-04-18 2023-10-04 抗ｒｏｒ抗体構築物

Publications (2)

Publication Number Publication Date
JP2021522162A true JP2021522162A (ja) 2021-08-30
JP2021522162A5 JP2021522162A5 (https=) 2022-04-25

Family

ID=68239890

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556851A Pending JP2021522162A (ja) 2018-04-18 2019-04-18 抗ｒｏｒ抗体構築物
JP2023172867A Withdrawn JP2023168551A (ja) 2018-04-18 2023-10-04 抗ｒｏｒ抗体構築物
JP2025117193A Pending JP2025137618A (ja) 2018-04-18 2025-07-11 抗ｒｏｒ抗体構築物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023172867A Withdrawn JP2023168551A (ja) 2018-04-18 2023-10-04 抗ｒｏｒ抗体構築物
JP2025117193A Pending JP2025137618A (ja) 2018-04-18 2025-07-11 抗ｒｏｒ抗体構築物

Country Status (15)

Country Link
US (2) US12084496B2 (https=)
EP (1) EP3797122A4 (https=)
JP (3) JP2021522162A (https=)
KR (1) KR20200143470A (https=)
CN (1) CN112384533A (https=)
AU (1) AU2019256431B2 (https=)
BR (1) BR112020021269A2 (https=)
CA (1) CA3097704A1 (https=)
EA (1) EA202092202A1 (https=)
IL (2) IL316574A (https=)
MX (4) MX2020010881A (https=)
MY (1) MY207121A (https=)
PH (1) PH12020551716A1 (https=)
SG (1) SG11202010235QA (https=)
WO (1) WO2019204564A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025526427A (ja) * 2022-07-26 2025-08-13 エイムド バイオ インコーポレイテッド 抗ｒｏｒ１抗体及びその用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110177805B (zh) * 2016-10-19 2024-04-02 英温拉公司 抗体构建体
EP4200336A4 (en) * 2020-08-24 2024-09-25 Epimab Biotherapeutics (HK) Limited Anti-ror1 antibodies and related bispecific binding proteins
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
US20230295276A1 (en) * 2022-03-18 2023-09-21 Novascope Biochips Inc. Antibody for porcine reproductive and respiratory syndrome virus and uses thereof
CA3259758A1 (en) * 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
WO2024207177A1 (en) * 2023-04-04 2024-10-10 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
GB202216284D0 (en) * 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation
AU2023409023A1 (en) * 2022-12-20 2025-07-31 Ho'ola Therapeutics Inc. Combination therapies for the treatment of cancer
WO2025019791A1 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Activatable ror binding agents and uses thereof
AU2024292307A1 (en) * 2023-07-20 2026-01-29 Exelixis, Inc. Tyrosine-protein kinase membrane receptor 1 (ror1) antibody-drug conjugates and uses thereof
WO2025019780A1 (en) * 2023-07-20 2025-01-23 Exelixis, Inc. Activatable tyrosine-protein kinase membrane receptor (ror) antibody-drug conjugates and uses thereof
WO2025132812A1 (en) * 2023-12-20 2025-06-26 Antalgenics, S.L. Phospholipase c inhibitor peptides and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011159847A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
WO2012075158A1 (en) * 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
JP2015532644A (ja) * 2012-08-24 2015-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
WO2017127702A1 (en) * 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
WO2017127499A1 (en) * 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
JP2018503380A (ja) * 2015-01-16 2018-02-08 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
CN110177805B (zh) 2016-10-19 2024-04-02 英温拉公司 抗体构建体
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
WO2011159847A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
WO2012075158A1 (en) * 2010-12-01 2012-06-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
US20130251642A1 (en) * 2010-12-01 2013-09-26 The United States of America, as represented by the secretary, Department of Heath and Human Servi Chimeric rabbit/human ror1 antibodies
JP2015532644A (ja) * 2012-08-24 2015-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
JP2017536341A (ja) * 2014-10-09 2017-12-07 エンクマフ アーゲー 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体
WO2016094873A2 (en) * 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
JP2018503380A (ja) * 2015-01-16 2018-02-08 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
WO2017127702A1 (en) * 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
WO2017127499A1 (en) * 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025526427A (ja) * 2022-07-26 2025-08-13 エイムド バイオ インコーポレイテッド 抗ｒｏｒ１抗体及びその用途

Also Published As

Publication number Publication date
AU2019256431A1 (en) 2020-11-05
MX2025001906A (es) 2025-04-02
KR20200143470A (ko) 2020-12-23
IL316574A (en) 2024-12-01
CN112384533A (zh) 2021-02-19
EA202092202A1 (ru) 2021-07-23
US12084496B2 (en) 2024-09-10
US20210155692A1 (en) 2021-05-27
SG11202010235QA (en) 2020-11-27
EP3797122A4 (en) 2022-04-20
MY207121A (en) 2025-01-31
WO2019204564A9 (en) 2019-12-12
EP3797122A1 (en) 2021-03-31
MX2025001902A (es) 2025-04-02
MX2025001900A (es) 2025-04-02
US20240392002A1 (en) 2024-11-28
JP2025137618A (ja) 2025-09-19
CA3097704A1 (en) 2019-10-24
JP2023168551A (ja) 2023-11-24
IL278061A (en) 2020-11-30
WO2019204564A1 (en) 2019-10-24
AU2019256431B2 (en) 2026-01-15
PH12020551716A1 (en) 2021-07-26
MX2020010881A (es) 2020-11-09
BR112020021269A2 (pt) 2021-03-16

Similar Documents

Publication Publication Date Title
US20240392002A1 (en) Anti-ror antibody constructs
JP7591015B2 (ja) 抗体構築物
KR102256152B1 (ko) Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도
US20250026861A1 (en) Trivalent trispecific antibody constructs
JP2022523197A (ja) Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
US20220213225A1 (en) Multispecific treg binding molecules
US20210163594A1 (en) Binding molecules
KR20230166120A (ko) 새로운 tnfr2 결합 분자
CN109627340B (zh) Cd3和prlr双特异性抗体及其构建与应用
US20210363265A1 (en) Multivalent receptor-clustering agonist antibody constructs
WO2020102647A1 (en) Multivalent receptor-clustering agonist antibody constructs and antigen binding proteins
US20220153844A1 (en) Multispecific treg binding molecules
KR20230079074A (ko) 면역글로불린 ｅ 항체 조성물 및 사용 방법
AU2026202585A1 (en) Anti-ror antibody constructs
JP2022527541A (ja) 抗ｈｌａ－ｃ抗体及びその使用
EA048615B1 (ru) Конструкции антител к ror
CN115181180B (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其应用
TW202608923A (zh) Ｌｔｂｒ結合分子及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240607